$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Hematology
Hematology
单独用维奈托克治疗慢淋白血病可以吗?
2025-10-19 11:44:20
Check Details
吉妥珠单抗适用于成人新诊断的髓系细胞分化抗原阳性急性髓性白血病
2025-10-19 11:44:20
Check Details
白血病患者使用维奈托克治疗时在饮食方面的注意事项
2025-10-19 11:44:20
Check Details
波舒替尼获FDA批准用于治疗新诊断的慢性期费城染色体阳性慢性粒细胞白血病
2025-10-19 11:44:20
Check Details
新发急性髓性白血病使用吉妥珠单抗治疗的效果
2025-10-19 11:44:20
Check Details
维奈托克适用于染色体17p缺失或复发/难治性慢性淋巴细胞白血病的治疗
2025-10-19 11:44:20
Check Details
波舒替尼是慢性髓系白血病的一线治疗药物
2025-10-19 11:44:20
Check Details
吉妥珠单抗治疗急性髓性白血病能活多久?
2025-10-19 11:44:20
Check Details
维奈托克目前经FDA批准的适应症有哪些?
2025-10-19 11:44:20
Check Details
白血病患者使用波舒替尼进行治疗的费用
2025-10-19 11:44:20
Check Details
阿卡拉布替尼是治疗白血病的第二代BTK抑制剂
2025-10-19 11:44:20
Check Details
吉妥珠单抗是治疗急性髓性白血病的药物
2025-10-19 11:44:20
Check Details
1
2
...
613
614
615
616
617
618
619
...
938
939
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Belumosudil for cGVHD: 200mg with Food, Pregnancy Contraception, Liver Monitoring, Drug Interactions
2
Acalabrutinib in CLL/SLL Survival Expectation: ELEVATE-TN and ASCEND Long-Term PFS, OS
3
Bosutinib for CML: Time to Response, BCR-ABL Monitoring, and Molecular Remission
4
Acalabrutinib Dosing and Combination Regimens: CLL/SLL, MCL, Safety Adjustments
5
Bosutinib for Ph+ CML: Indications, Dosing Adjustments, and Hepatic/Renal Safety
6
AZA+VEN+IVO Triplet Therapy for Newly Diagnosed IDH1 AML: High Response Rates and Durable Efficacy
7
Anagrelide and Myelofibrosis Risk: Controversy and Monitoring in ET Treatment
8
Acalabrutinib Dosing Guide: Dosage, Duration and Precautions
9
Enasidenib: A Targeted IDH2 Inhibitor for Acute Myeloid Leukemia
10
Ponatinib in Chronic Myeloid Leukemia: 5-Year Results from the OPTIC Trial
11
Midostaurin (Rydapt): Dosing Essentials in FLT3-Mutated AML and Systemic Mastocytosis
12
Bosutinib Indications Explained: CML Targeted Therapy and ADPKD Research Insights